1. Scrip
  2. >>Business
  3. >>Strategy

Beckley Psytech Takes Another Step Toward Psychedelic Antidepressants

 
• By Alaric DeArment

The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.

5-MeO-DMT occurs in a number of plant and animal species, including the beans of the tree species Anadenanthera peregrina, also known as yopo • Source: Shutterstock

Beckley Psytech Limited bolstered its case for psychedelic treatment of depression with Phase IIa data released as the company runs a separate Phase IIb study that it calls the largest US Food and Drug Administration-approved trial of its kind.

The privately held, Oxford, UK-based company announced 27 March positive data from its Phase IIa study of BPL-003, a formulation of the psychedelic drug 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT) in treatment-resistant depression (TRD)

Key Takeaways

  • Beckley Psytech announced positive data from a small number of patients in a Phase IIa study of BPL-003 in treatment-resistant depression, with a 55% response rate after a single dose.

  • The company said the data support its ongoing Phase IIb trial, which is enrolling 225 patients at 40 sites in North America, Australia and Europe

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.